New Hemab Therapeutics (COAG) director files initial ownership report

Rhea-AI Filing Summary

Hemab Therapeutics Holdings, Inc. filed an insider ownership report identifying Laura Tadvalkar as a director. The Form 3 data show no buy, sell, or other stock transactions, indicating this filing simply establishes her status as a reporting person for the company’s shares.

Key Terms

Form 3, insider filing data, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): insider ownership report for Hemab Therapeutics"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

insider filing data regulatory

"INSIDER FILING DATA (Form 3): structured insider filing data for the issuer"

reporting person financial

"The Form 3 data identify Laura Tadvalkar as a reporting person for the company"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tadvalkar Laura

(Last) (First) (Middle)

C/O HEMAB THERAPEUTICS HOLDINGS, INC.

101 MAIN STREET, SUITE 1220

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/30/2026

3. Issuer Name and Ticker or Trading Symbol
Hemab Therapeutics Holdings, Inc. [ COAG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

24.1 Power of Attorney

No securities are beneficially owned.

	/s/ Mads Nikolaj Behrndt-Eriksen, as Attorney-in-Fact	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Hemab Therapeutics (COAG) Form 3 filing show about Laura Tadvalkar?

The Form 3 identifies Laura Tadvalkar as a director of Hemab Therapeutics Holdings, Inc. It lists her as a reporting person for COAG but shows no stock transactions or specific share holdings in the available data from this filing.

Are any stock transactions reported for COAG in Laura Tadvalkar’s Form 3?

No stock transactions are reported in this Form 3. All summarized transaction counts, including buys, sells, exercises, gifts, and tax withholdings, are zero, indicating the filing is a baseline insider ownership report without trading activity disclosed.

What is the significance of a Form 3 for Hemab Therapeutics (COAG)?

A Form 3 is an insider ownership report that identifies an individual as a reporting person for a company’s securities. For Hemab Therapeutics, it formally records Laura Tadvalkar’s status as a director, preparing the basis for any future reportable transactions.

Does the COAG Form 3 filing disclose derivative positions for Laura Tadvalkar?

The available Form 3 data show no derivative positions for Laura Tadvalkar. The derivative summary is empty and derivative transaction counts are zero, so no options, warrants, or other derivative securities are listed in this particular filing excerpt.

Who is the reporting person in this Hemab Therapeutics (COAG) Form 3?

The reporting person is Laura Tadvalkar, identified as a director of Hemab Therapeutics Holdings, Inc. She is not listed as an officer or ten percent owner in the data, and the filing contains no associated stock or derivative transactions.